Axitinib is a small-molecule protein-tyrosine kinase receptor inhibitor specifically targeting this family of receptors, in addition to platelet-derived growth factor receptor and proto-oncogene c-Kit.
Improved knowledge of kidney cancer development, and specifically mutations in the VHL gene, has supported the targeting of angiogenesis pathways. Axitinib is the most recently approved agent for use in metastatic renal cell carcinoma. This review will focus on the preclinical pharmacology, pharmacokinetics and clinical activity of this agent, and describe its place in the current treatment of renal cell carcinoma.
Written by:
Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A. Are you the author?
University of Colorado School of Medicine, Division of Medical Oncology, Denver, Colorado 80045, USA.
Reference: Drugs Today (Barc). 2012 Oct;48(10):633-44.
doi: 10.1358/dot.2012.48.10.1860768
PubMed Abstract
PMID: 23110259
UroToday.com Renal Cancer Section
